CCTG Clinical Trials
Public Trial Select
Member Trial Select
Protecting Cancer Patients from COVID-19In the race to find new ways to prevent and treat COVID-19, CCTG has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients. More >> |
Recently Activated Trials
Member Links
CCTG Announces Initiation of IND.239CCTG has announced the commencement of a Phase II study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer. More >> |
Planned Trials
Committees Select
Group newsletter: CCTG Connection
July 15, 2020
CO.26 Primary Publication and Other Recent PublicationsPublished: July 15, 2020Category: Publications  There were four recent publications, including the primary publication for CCTG CO.26: A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients with Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies. Read More |
|
|
June 24, 2020
CCTG Phase III Team Award - CE.8 Princess Margaret Cancer CentrePublished: June 24, 2020Category: News  CCTG is pleased to announce that the 2020 CCTG Phase III Team Award for Intergroup-Led trials has been awarded to the Princess Margaret Cancer Centre CE.8 trial team based on the centre's accrual metrics both overall and for this past year, local activation timelines, and compliance metrics. Read More |
 CCTG is pleased to announce that the 2020 CCTG Phase III Team Award for Intergroup-Led trials has been awarded to the Saskatoon Cancer Centre MAC.21 trial team based on the centre's accrual metrics both overall and for this past year, local activation timelines, and compliance metrics. The team members include: Nayyer Iqbal, Osama Ahmed, Shahid Ahmed, Tehmina Asif, Kamal Haider, Amer Sami, Mita Manna, Andrea Gallivan, Dominique Wagner, Jolene Hicks. Read More |
 CCTG is pleased to announce that the 2020 CCTG IND Team Award has been awarded to the BCCA Vancouver Centre IND.234 trial team based on the centre's accrual metrics both overall and for this past year, local activation timelines, and compliance metrics. The team members include: Kim Chi, Manahil Sadiq, Julita Sienkiewicz, and Wendy Won. Read More |
Dr. Lillian Siu - 2020 Recipient of the International Women Who Conquer Cancer Mentorship AwardPublished: June 24, 2020Category: News  CCTG is very proud to announce that Dr. Lillian Siu, Princess Margaret Cancer Centre, has been chosen as the recipient of the 2020 International Women Who Conquer Cancer Mentorship Award. Dr. Siu is the director of the Phase I Program, co-director of the Bras and Family Drug Development Program, and clinical lead for the Tumor Immunotherapy Program at Princess Margaret and is Co-Chair of CCTG's Head and Neck Site Committee. She also holds the BMO Chair in Precision Genomics. Read More |
 Two CCTG researchers were recently awarded nearly $2 million from the Canadian Cancer Society and the Conquer Cancer-Breast Cancer Research Foundation to support conduct of CCTG Investigational New Drug trials. Read More |
Dr. Tim Whelan - 2020 Recipient of the CCTG Founder's Award - Dr. Joseph Pater Excellence in Clinical Trials ResearchPublished: June 24, 2020Category: News  CCTG is very pleased to announce that Dr. Tim Whelan is the 2020 recipient of the CCTG Founder's Award - Dr. Joseph Pater Excellence in Clinical Trials Research. This award honours an investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer. This individual's research has provided techniques, information or concepts that will direct the future of the oncology research community and CCTG. Read More |